Nov
DEC
Jan
21
2014
2015
2016
1 captures
21 Dec 15 - 21 Dec 15
Close
Help
Skip to main content
Access brought to you by:
LOCKSS
Login
Search for this keyword
Advanced Search
Main menu
HOME
BROWSE BY CONFERENCE
BROWSE BY DISCIPLINE
-- All Disciplines --
Anesthesiology
Cardiology & Cardiovascular Medicine
Dentistry
Dermatology
Endocrinology, Diabetes & Metabolism
Emergency Medicine & Critical Care
Hematology
Hepatology
Infectious Diseases
Nephrology
Neurology
Nutrition
Obstetrics & Gynecology
Oncology
Ophthalmology
Orthopaedics & Sports Medicine
Psychiatry & Psychology
Pulmonary & Respiratory Medicine
Radiology
Rheumatology
Veterinary Medicine
ABOUT
About Us
International Medical Advisory Board
Reprints
Librarian resources
Contact us
Help
Introduction
American Society of Hematology, 56th Annual Meeting & Exposition: Advisors’ Introduction
Featured Articles
Advances and Challenges in Sickle Cell Anemia
Clinical Trial Highlights
JAK2-STAT3 Signaling Implicated in the Regulation of Hepatic TPO Production
AALL0434 Treatment Therapy Has Excellent Outcomes in Children With T-ALL
Clonal Mapping of Hematopoiesis In Vivo Provides Direction for New Clinical Protocols
Activity of Lenalidomide in MDS Tied to Degradation of CSNK1A1
Th17-Prone CD146
+
CCR5
+
T-Cell Population Is an Early Marker of Intestinal GVHD
Sorafenib as Effective Treatment for Newly Diagnosed AML in Younger Patients
FXI-ASO May Represent a New Class of Antithrombotic Agents
Benefit of Extended Anticoagulation After Unprovoked PE Lost After Treatment Discontinuation
Tinzaparin Reduces the Risk of Recurrent Thromboembolic Events in Patients With Cancer
AZA Plus LEN or VOR Do Not Improve Response Rates in MDS or CMML, Though DFS and OS Still an Open Question
Idarucizumab Reverses Dabigatran in Elderly or Renally Impaired
Vosaroxin in Combination With Cytarabine Provides a New Salvage Option for AML
FCR Superior in Treatment of Advanced CLL
CKT Implicated in Worse Outcomes With Ibrutinib Therapy of CLL
MRD and Clinical Response Predictors of PFS in CLL
Noninvasive Detection of Genomic Imbalances in HL Is Promising
Dasatinib Outcomes Maintained Over 5 Years
Reduced-Dose Conditioning Comparable to Standard Dose Prior to ASCT in MDS
4F-PCC Reverses Apixaban Anticoagulation in Healthy Volunteers
PCC Reverses Dabigatran-Associated Bleeding in Polytrauma Model
Selected Updates
Coagulation Therapy and Thrombosis
Insights Into Pathophysiology of Lymphomas Help Identify Therapeutic Targets
Treatment Paradigms for MPNs Continue to Evolve
ASCT for Multiple Myeloma: The Role of the Novel Agents
Back to top
Previous
Next
Search for this keyword